IQVIA Holdings Inc (IQV)

In February 2026, IQVIA's stock experienced a significant decline following its Q4 2025 earnings report due to broader investor concerns, despite beating analyst estimates. In March 2026, IQVIA unveiled IQVIA.ai, and Barclays and TD Cowen upgraded their ratings or targets for IQVIA. In May 2026, IQVIA reported its Q1 2026 results, surpassing both earnings and revenue forecasts, and announced a $2 billion increase in its share repurchase authorization.

Demand for IQVIA's products and services exhibits some seasonality, with first-quarter results typically trailing the prior period. The pharmaceutical CRO industry generally benefits from rising clinical trial complexity and increased R&D outsourcing trends. There are lingering concerns among investors that advancements in AI could potentially allow biopharma clients to bring more trial-related work in-house. IQVIA's Q1 2026 results showed strong acceleration of organic revenue growth in both Commercial Solutions and Research & Development Solutions segments, driven by demand for AI-enabled solutions and new drug launches.

IQVIA Holdings, Inc. is a global leader providing advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA operates within the health technology sector, encompassing industries such as CRO, pharmaceutical services, AI, IT, and consulting. The company's core business involves creating intelligent connections across healthcare through its analytics, transformative technology, extensive data resources, and deep domain expertise. IQVIA's major products and services are delivered through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Headquartered in Durham, North Carolina, U.S., IQVIA has a significant international presence, conducting operations in over 100 countries. The company has strategically expanded its footprint across North America, South America, Europe, Africa, and Asia-Pacific, with major offices in locations such as Danbury, Buenos Aires, Melbourne, and multiple cities across Europe. This widespread network supports its diverse customer base and ensures localized delivery and global reach.

IQVIA has maintained a strong brand reputation, evidenced by its consistent recognition on prestigious lists. IQVIA was named No. 1 in its sector on the 2026 Fortune® World's Most Admired Companies™ list for the fifth consecutive year. However, IQVIA has faced criticism in the past for collecting and selling anonymized patient medical records.

IQVIA's ownership is predominantly held by institutional investors, who collectively owned approximately 92.35% of the company's outstanding shares as of March 2025. Major institutional shareholders include The Vanguard Group, BlackRock Institutional Trust Company, Harris Associates L.P., State Street Investment Management, GIC Private Limited, Geode Capital Management, CPP Investments, AllianceBernstein L.P., Boston Partners and Artisan Partners Limited Partnership. Insider ownership stands at 6.31%. Recent insider activity includes a sale of 36,564 shares by CEO Ari Bousbib in the past six months.